Research Paper Volume 12, Issue 18 pp 18192—18208

MicroRNA-216a-3p promotes sorafenib sensitivity in hepatocellular carcinoma by downregulating MAPK14 expression

class="figure-viewer-img"

Figure 6. MiR-216-3p expression correlates with treatment response and prognosis of HCC patients treated with sorafenib. (A) Q-PCR analysis shows miR-216a-3p levels in pretreatment tumor tissues (biopsy) from patients showing different (poor, moderate or high) response to sorafenib treatment. As shown, patients with good response have significantly higher miR-216a-3p expression compared to those with poor response. (B) Kaplan Meier survival curve analysis shows disease-free survival of HCC patients with high or low miR-216-3p expression in the tumor tissues. As shown, DFS rates are significantly higher for HCC patients with high miR-216a-3p levels compared to those with low miR-216a-3p levels.